Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total ...

Crofelemer can potentially extend and save lives of microvillus inclusion disease patients, reducing the volume of the total parenteral support (PS) necessary for them to surviveGroundbreaking PS redu ...

Q3 2025 Earnings Call Transcript November 12, 2025 CorMedix Inc. beats earnings expectations. Reported EPS is $1259.23, ...

Request To Download Free Sample of This Strategic Report @ In 2018, the Clinical Nutrition Market reached a valuation of $313.578 billion, indicating a robust foundation for growth. Over the forecast ...

Early diagnosis of reactive infectious mucocutaneous eruption is important to minimize potential long-term disease ...

Napo Pharmaceuticals provided a recap of the November 8, 2025 presentation at the North American Society for Pediatric ...

Two year old Ruby suffers from a rare metabolic condition and is one of the stars of Great Ormond Street Hospital Charity’s ...

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...

Extremely preterm infants with higher fat-free mass at term-equivalent age show better cognitive, language, and motor ...

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-thr ...

CorMedix again raises its full-year 2025 pro forma net revenue guidance to a range of $390 to $410 million, and fourth quarter net revenue guidance to a range of $115 to $135 million. In addition, the ...